Key result
mRNA COVID-19 vaccines are linked to steroid-responsive eosinophilic myocarditis driven by cationic protein release.
Why the study?
Severe myocarditis may occur after COVID-19 mRNA (BNT162b2) vaccination, but its pathway, morphomolecular characterization, and treatment remain unknown.
Does prednisone improve cardiac contractility in patients with hypersensitivity eosinophilic myocarditis following COVID-19 mRNA vaccination?
Population
3 patients with severe conduction tissue or cardiac function compromise after COVID-19 mRNA vaccination
Design
Case series
Authors
Loading...
May warrant vigilance for eosinophilic myocarditis post-mRNA vaccination; hypothesis-generating and requires prospective confirmation.
Case Report (n=3)
Does prednisone improve cardiac contractility in patients with hypersensitivity eosinophilic myocarditis following COVID-19 mRNA vaccination?
Severe myocarditis following COVID-19 mRNA vaccination can be mediated by an eosinophilic hypersensitivity reaction that responds well to a short course of corticosteroids.
Frustaci et al. (2022) conducted a case report in Hypersensitivity Myocarditis after COVID-19 mRNA Vaccination (n=3). COVID-19 mRNA (BNT162b2) vaccination was evaluated on Histological findings and response to steroid administration. Eosinophilic myocarditis is a possible adverse reaction to the mRNA COVID-19 vaccine, mediated by cationic protein release, and responds to short courses of steroid administration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: